Mauricio Romero-Gonzalez1,2, Abtin Shahanaghi1,3, Gregory J DiGirolamo1,4,5, Gerardo Gonzalez1,2,6. 1. Division of Addiction Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. 2. MAYU of New England, New Haven, Connecticut. 3. Department of Psychiatry, Boston University, Boston, Massachusetts. 4. College of the Holy Cross, Worcester, Massachusetts. 5. Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts. 6. VA Central Western Massachusetts Healthcare System, Leeds, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Opioid use disorder among young adults is rising sharply with an increase in morbidity and mortality. This study examined differences in treatment response to a fixed dose of buprenorphine-naloxone between heroin (HU) and prescriptions opioids (POU) users. METHODS: Eighty opioid dependent young adults (M = 22 years) were treated with buprenorphine-naloxone 16-4 mg/day for 8 weeks. Differences between HU (N = 17) and POU (N = 63) on changes in weekly opioid use, opioid craving, withdrawal, and depression symptoms were analyzed with mixed-effects regression models. RESULTS: The HU had an overall mean proportion of weekly opioid use of .32 (SD = .14) compared to POU's weekly mean of .24 (SD = .15) showing a significant main effect (Z = 2.21, p = .02). Depressive symptoms (CES-D scores) were elevated at baseline for both groups (HU: M = 23.1, SD = 11.9; PO: M = 22.2, SD = 9.4), but only POU improved significantly to a score of 9.88 (SD = 7.4) compared to HU's score of 18.58 (SD = 10.3) at week 8 (Z = 2.24, p = .02). There were no significant differences in treatment retention, craving, or withdrawal symptoms. DISCUSSION AND CONCLUSIONS: Treatment response to 16-4 mg/day of buprenorphine-naloxone was significantly diminished for heroin users relative to opioid prescription users in weekly opioid use. Heroin users also had persistent depressive symptoms suggesting the need for close monitoring. SCIENTIFIC SIGNIFICANCE: These data suggest that young heroin users might require higher doses of buprenorphine. (Am J Addict 2017;26:838-844).
BACKGROUND AND OBJECTIVES: Opioid use disorder among young adults is rising sharply with an increase in morbidity and mortality. This study examined differences in treatment response to a fixed dose of buprenorphine-naloxone between heroin (HU) and prescriptions opioids (POU) users. METHODS: Eighty opioid dependent young adults (M = 22 years) were treated with buprenorphine-naloxone 16-4 mg/day for 8 weeks. Differences between HU (N = 17) and POU (N = 63) on changes in weekly opioid use, opioid craving, withdrawal, and depression symptoms were analyzed with mixed-effects regression models. RESULTS: The HU had an overall mean proportion of weekly opioid use of .32 (SD = .14) compared to POU's weekly mean of .24 (SD = .15) showing a significant main effect (Z = 2.21, p = .02). Depressive symptoms (CES-D scores) were elevated at baseline for both groups (HU: M = 23.1, SD = 11.9; PO: M = 22.2, SD = 9.4), but only POU improved significantly to a score of 9.88 (SD = 7.4) compared to HU's score of 18.58 (SD = 10.3) at week 8 (Z = 2.24, p = .02). There were no significant differences in treatment retention, craving, or withdrawal symptoms. DISCUSSION AND CONCLUSIONS: Treatment response to 16-4 mg/day of buprenorphine-naloxone was significantly diminished for heroin users relative to opioid prescription users in weekly opioid use. Heroin users also had persistent depressive symptoms suggesting the need for close monitoring. SCIENTIFIC SIGNIFICANCE: These data suggest that young heroin users might require higher doses of buprenorphine. (Am J Addict 2017;26:838-844).
Authors: Adrienne J Heinz; David H Epstein; Jennifer R Schroeder; Edward G Singleton; Stephen J Heishman; Kenzie L Preston Journal: J Subst Abuse Treat Date: 2006-08-01
Authors: Michael A Yokell; M Kit Delgado; Nickolas D Zaller; N Ewen Wang; Samuel K McGowan; Traci Craig Green Journal: JAMA Intern Med Date: 2014-12 Impact factor: 21.873
Authors: Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss Journal: Drug Alcohol Depend Date: 2013-01-18 Impact factor: 4.492
Authors: Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta Journal: Neuropsychopharmacology Date: 2003-11 Impact factor: 7.853
Authors: Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld Journal: J Gen Intern Med Date: 2007-04 Impact factor: 5.128
Authors: Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222